News

A new exploratory evaluation of a previous study has now provided further evidence of the effectiveness of OkuStim® therapy. The data show that after one year of TES treatment, visual field deterioration in patients with retinitis pigmentosa (RP) was slowed depending on the stimulation intensity.

We are pleased to have won two new partners in the provision of the OkuStim therapy for you: the Augenzentrum Frankfurt and Teichmann Ohren- und Augenwelt.

Short waiting times for appointments, good transport connections and international expertise are now available close to you.

A recent social court ruling paves the way for the retroactive reimbursement of OkuStim therapy for retinitis pigmentosa (RP). A patient had filed a lawsuit because her health insurance company had refused to cover the costs, as there was no threat of blindness and the therapeutic benefit of TES had not yet been evaluated by the Federal Joint Committee (G-BA).

The amendment of the ophthalmological guideline for hereditary retinal, choroidal and visual pathway diseases now also refers to electrical stimulation as a therapy option for retinitis pigmentosa (RP). This gives ophthalmologists a concrete option for the symptomatic treatment of RP.

Retina UK's professional and annual conferences will be held online in April. Registration is now open.
We will be presenting OkuStim Therapy as part of the "Update from Industry" session in the Annual Conference programme on 17 April.
OkuStim therapy has been available in the UK since December 2020.

Most of the more than 6,000 different rare diseases are of genetic origin. Retinitis Pigmentosa (RP) is one of them.
There are therapies for only about 3% of rare diseases - OkuStim therapy for RP is one of them. It can preserve vision.

OkuStim therapy is now available for you in the UK.

Please follow the link for contact details.